Palisade Bio (PALI) Competitors $1.75 -0.05 (-2.78%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends PALI vs. INDP, CYCN, MYNZ, EGRX, BCDA, VCNX, MBIO, RDHL, GNPX, and BCLIShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Indaptus Therapeutics (INDP), Cyclerion Therapeutics (CYCN), Mainz Biomed (MYNZ), Eagle Pharmaceuticals (EGRX), BioCardia (BCDA), Vaccinex (VCNX), Mustang Bio (MBIO), RedHill Biopharma (RDHL), Genprex (GNPX), and Brainstorm Cell Therapeutics (BCLI). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Indaptus Therapeutics Cyclerion Therapeutics Mainz Biomed Eagle Pharmaceuticals BioCardia Vaccinex Mustang Bio RedHill Biopharma Genprex Brainstorm Cell Therapeutics Indaptus Therapeutics (NASDAQ:INDP) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership. Does the media prefer INDP or PALI? In the previous week, Palisade Bio had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for Palisade Bio and 0 mentions for Indaptus Therapeutics. Palisade Bio's average media sentiment score of 0.45 beat Indaptus Therapeutics' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the news media. Company Overall Sentiment Indaptus Therapeutics Neutral Palisade Bio Neutral Do analysts recommend INDP or PALI? Indaptus Therapeutics presently has a consensus target price of $8.50, indicating a potential upside of 806.18%. Palisade Bio has a consensus target price of $23.00, indicating a potential upside of 1,214.29%. Given Palisade Bio's higher possible upside, analysts plainly believe Palisade Bio is more favorable than Indaptus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Palisade Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is INDP or PALI more profitable? Palisade Bio's return on equity of -148.51% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -177.27% -141.06% Palisade Bio N/A -148.51%-115.16% Do institutionals and insiders believe in INDP or PALI? 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 29.5% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 3.3% of Palisade Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, INDP or PALI? Indaptus Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Palisade Bio has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Which has better valuation & earnings, INDP or PALI? Palisade Bio has higher revenue and earnings than Indaptus Therapeutics. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.42M-$1.71-0.55Palisade Bio$250K10.60-$12.30M-$13.98-0.13 Does the MarketBeat Community believe in INDP or PALI? Indaptus Therapeutics received 3 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 86.67% of users gave Indaptus Therapeutics an outperform vote while only 50.00% of users gave Palisade Bio an outperform vote. CompanyUnderperformOutperformIndaptus TherapeuticsOutperform Votes1386.67% Underperform Votes213.33%Palisade BioOutperform Votes1050.00% Underperform Votes1050.00% SummaryPalisade Bio beats Indaptus Therapeutics on 9 of the 14 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.65M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-0.1346.7390.0517.18Price / Sales10.60415.011,116.25117.06Price / CashN/A182.1043.1037.85Price / Book0.103.894.784.78Net Income-$12.30M-$42.21M$120.31M$225.60M7 Day Performance-1.13%-2.15%-1.92%-1.23%1 Month Performance-28.28%1.73%13.65%0.46%1 Year Performance-80.49%16.36%28.34%15.24% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio2.8197 of 5 stars$1.75-2.8%$23.00+1,214.3%-80.4%$2.65M$250,000.00-0.1310INDPIndaptus Therapeutics2.8694 of 5 stars$0.98-2.0%$8.50+767.3%-49.6%$9.99MN/A-0.586CYCNCyclerion Therapeutics0.6395 of 5 stars$3.65+6.4%N/A-22.2%$9.89M$194,000.000.0030Gap DownMYNZMainz Biomed2.4955 of 5 stars$4.90-8.6%$120.00+2,349.0%-85.7%$9.81M$917,203.00-0.0730News CoverageGap UpEGRXEagle Pharmaceuticals1.0024 of 5 stars$0.75+36.4%N/A-89.0%$9.74M$257.55M0.00134Gap DownBCDABioCardia3.3044 of 5 stars$2.09+0.5%$25.00+1,096.2%-79.8%$9.58M$71,000.00-0.5016Analyst ForecastShort Interest ↓Positive NewsGap UpVCNXVaccinex0.9792 of 5 stars$3.60-2.4%N/A-85.7%$9.36M$570,000.00-0.0840Positive NewsMBIOMustang Bio2.1494 of 5 stars$0.19-0.4%$2.00+938.4%-86.3%$9.20MN/A-0.12100Positive NewsRDHLRedHill Biopharma0.4399 of 5 stars$7.16-3.8%N/A-99.2%$9.17M$3.71M0.00210Gap DownGNPXGenprex3.942 of 5 stars$1.06-8.6%$10.00+843.4%-89.1%$9.02MN/A0.0020Gap UpBCLIBrainstorm Cell Therapeutics4.0861 of 5 stars$1.55+6.9%$30.00+1,835.5%-21.2%$8.84MN/A-0.3040Gap Up Related Companies and Tools Related Companies INDP Alternatives CYCN Alternatives MYNZ Alternatives EGRX Alternatives BCDA Alternatives VCNX Alternatives MBIO Alternatives RDHL Alternatives GNPX Alternatives BCLI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PALI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredTech funds are hemorrhaging cash: Sell this stock nowSomething very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PALI Stock Alerts